pharma · COVID-19 · Cystic Fibrosis · ARCT
Arcturus Therapeutics
Arcturus Therapeutics Holdings
Arcturus Therapeutics patent portfolio — 55 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 10285 Science Center Dr, San Diego, California 92121, US
- Founded
- 2013
- Employees
- 157
- Programs
- 13
- Drugs
- 7
- Patents
- 55
Arcturus Therapeutics patents
55 pharmaceutical patents indexed for Arcturus Therapeutics. 0 expire within 24 months.
Arcturus Therapeutics has 55 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 9580711
Lipid particles with asymmetric cationic lipids for RNA delivery
granted -
US 9567296
Ionizable cationic lipid for RNA delivery
granted -
US 9365610
Asymmetric ionizable cationic lipid for RNA delivery
granted -
US 9340789
UNA oligomer structures for therapeutic agents
granted -
US 9303260
UNA duplex oligomers for therapeutics
granted -
US 9297009
UNA oligomers targeting micro-RNA for therapeutics
granted -
US 9051570
UNA oligomers for therapeutics
granted
Frequently asked questions
How many patents does Arcturus Therapeutics have?
55 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Arcturus Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.